An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Skyway Capital Markets announces the merger of SeaStar Medical, a medical technology firm, with LMF Acquisition Opportunities (NASDAQ: LMAO), a publicly traded SPAC. This merger aims to enhance SeaStar Medical’s access to capital markets, accelerating the development of its therapies for acute kidney injury (AKI) in pediatric and adult patients. The patented Selective Cytopheretic Device will seek FDA approval for commercialization. Skyway served as the sole financial advisor for LMAO in this significant business combination.
Positive
Access to capital markets for SeaStar Medical.
Potential acceleration in developing therapies for acute kidney injury.
FDA approval pathway for the Selective Cytopheretic Device.
Negative
None.
TAMPA, Fla.--(BUSINESS WIRE)--
Skyway Capital Markets, LLC (“Skyway”) is pleased to announce the merger of SeaStar Medical, Inc. (“SeaStar Medical”), a medical technology company developing extracorporeal therapies to reduce the consequences of excessive inflammation on vital organs, and LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) (“LMAO”), a publicly traded special purpose acquisition company. Skyway Capital Markets LLC served as sole financial and valuation advisor to LMAO in connection with the proposed business combination.
Skyway Capital Markets announces the merger of SeaStar Medical, Inc. (“SeaStar Medical”), a medical technology company developing extracorporeal therapies to reduce the consequences of excessive inflammation on vital organs, and LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) (“LMAO”), a publicly traded special purpose acquisition company. Skyway Capital Markets LLC served as sole financial and valuation advisor to LMAO in connection with the proposed business combination.
The transaction is expected to provide SeaStar Medical with access to the capital markets and thereby position the company to accelerate the development and advancement of its lead programs for acute kidney injury (AKI) in both pediatric and adult patients, as well as advance other SeaStar Medical programs in acute and chronic indications.
SeaStar Medical’s Selective Cytopheretic Device (“SCD”) is a patented, cell-directed, extracorporeal immunomodulator that selectively targets activated neutrophils and monocytes to address hyperinflammation. Neutrophils and monocytes are the cellular mediators that drive systemic inflammation, which when spreading uncontrollably through the body can lead to organ damage, organ failure or death. The SCD technology targets the cellular drivers of inflammation to restore balance in the body and potentially reverse the damage. SeaStar Medical intends to submit SCD for approval with the FDA under the Humanitarian Device Exemption to commence commercialization for the treatment of pediatric AKI and advance SCD into a pivotal trial for treatment of AKI in adults.
LMAO CEO, Bruce Rodgers, commented “We consulted with the Skyway team informally throughout our search for a SPAC target. Skyway understands private, public, and SPAC M&A transactions and is able to explain their nuanced differences to target ownership. The Seastar opportunity was presented on a tight timeline. Skyway’s health care and medical device industry depth allowed us to evaluate this transaction within the required timeline to reach definitive agreement. . We are excited for what the future holds for SeaStar Medical with LMAO’s financial resources behind them.”
Russ Hunt, CEO of Skyway Capital Markets, commented “With over 600 special purpose acquisition companies racing against the clock to find and close a transaction before their vehicles expire, in an environment where very few are actually succeeding, we are incredibly proud of our team at Skyway for getting this transaction across the finish line. We are even more proud of the quality of the target brought to the table and the future growth potential LMAO investors will now have access to. Healthcare and technology continue to be attractive sectors and we remain highly active in both.”
Skyway Capital Markets Chairman, Marty Traber, added “Our family and founder owned business clients ask us regularly about SPACs as options for growth capital and or partial liquidity events. We tell our clients that SPACs can be a great option for the right situation, but they are not easy transactions to close. Hiring the right M&A advisor is always important, but even more so when it comes to successfully executing a SPAC transaction.”
Skyway Capital Markets, LLC is a leading M&A advisor to closely held, founder-owned, family-owned middle-market businesses, and select public companies.
About Skyway Capital Markets
Skyway Capital Markets is a nationwide, market-leading, award winning boutique investment bank with a strong presence in the tech and telecom sectors. The firm works with middle market companies, public and private, through customized financial advisory services including corporate finance, capital raises, public and private offerings, mergers & acquisitions, fairness opinions, restructurings, and recapitalizations. Skyway Capital Markets is headquartered in Tampa, Florida and is a member of FINRA and SIPC. For additional information, please visit www.skywaycapitalmarkets.com.
About SeaStar Medical, Inc.
Denver-based SeaStar Medical is a privately-held medical technology company that is focusing on redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically-ill patients. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit http://seastarmedical.com/.
About LMF Acquisition Opportunities, Inc.
LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.. LMAO is led by Bruce M. Rodgers, Chief Executive Officer and Chairman of the Board. For more information, visit www.lmfacquisitions.com.
